

S'pore's industrial production slumped 9.3% yoy in November

Selena Ling

Head of Research and Strategy

+65 6530 4887

LingSSSelena@ocbc.com

Highlights

S'pore's industrial production slumped 9.3% yoy (-9.4% mom sa) in November, significantly underperforming expectations for -0.8% yoy (-0.3% mom sa) according to the Bloomberg consensus forecast. This data also marked a return to contraction after two consecutive months of positive on-year growth and is also the largest decline registered since December 2015 (-11.9% yoy). Meanwhile the October reading was also revised lower to 3.6% yoy (+3.0% mom sa), down from the initial estimates of 4.0% yoy (3.4% mom sa). **This brought the first eleven months' manufacturing performance to -1.6% yoy, or -4.1% yoy excluding the biomedical cluster.**

The slump was driven mainly by electronics which contracted 20.9% yoy in November, reversing the 0.9% yoy growth seen in October, and reinforces the "fits and starts" recovery theme for global semiconductor demand. The main drags came from computer peripherals (-31.8% yoy) and semiconductors (-25.7% yoy) which more than offset growth in other industry segments like infocomms and consumer electronics (+29.8% yoy) and data storage (+23.1% yoy). Note both the domestic manufacturing and electronics PMIs had both improved to 49.8 and 49.7 respectively in November, from 49.6 and 49.3 in October, but stayed shy of the 50 expansion threshold for now, suggesting that a clear turnaround for the sector was not on the cards yet. Notwithstanding the Phase 1 of the US-China trade agreement, the road ahead for the manufacturing and electronics recovery may remain bumpy.

Adding to the weakness was the biomedical cluster whose output also fell 10.3% yoy in November, due to a plunge in the output for pharmaceuticals (-12.7% yoy) and medical technology (-4.3% yoy). This is also the first yoy contraction in the biomedical cluster since September 2018 (-9.7% yoy). The contraction in the pharmaceutical output was attributed to a different mix of active pharmaceutical ingredients and biological products produced, but is illustrative of the volatility inherent in the biomedical cluster. Excluding the biomedical cluster, the manufacturing output decreased 9.0% yoy (-8.4% mom sa) in November.

Outside of the key electronics and biomedical clusters, the other manufacturing segments did not fare so badly. Namely, the precision engineering output rose 9.7% yoy, lifted by the machinery & systems segment (+10.6% yoy) amid increased activity in front-end semiconductor equipment and mechanical engineering work, as well as higher output in optical products and other metal precision components. Output for the transport engineering cluster also grew 2.1% yoy last month, as a strong

aerospace performance (+15.3% yoy) led by repair and maintenance job pipeline from commercial airlines which offset lower land (-1.9% yoy) and marine & offshore (-10.4% yoy) segments.

The November manufacturing output data was clearly a negative surprise to the recent green shoots theme developing in the global and regional economic landscape. We tip 4Q19 GDP growth estimates, which are due on Thursday 2 January 2020, to come in around 0.2% yoy (-1.6% qoq saar). This implies that the full-year 2019 GDP growth could be around 0.5% yoy, which is at the lower end of the official growth forecasts. This assumes that despite the much larger than expected November manufacturing output slump, the December manufacturing output could stabilize around -2.5% yoy and 4Q19 manufacturing growth could materialise at -2.7% (which is worse than 3Q19's -0.9% yoy print but less severe than 2Q19's -2.9% yoy). Our 2020 GDP growth forecast for the Singapore economy remains at 1-2% yoy, predicated on a modest manufacturing recovery with the services and construction sectors providing the growth bulwark. Since global monetary policy accommodation appears to have largely run its course for now, the onus will turn to fiscal policy stimulus to come to the rescue of tepid demand conditions. For Singapore, the upcoming 2020 Budget will also be a key focus.

Treasury Research & Strategy

Macro Research

Selena Ling
Head of Research & Strategy
LingSSSelena@ocbc.com
Tommy Xie Dongming
Head of Greater China Research
XieD@ocbc.com
Wellian Wiranto
Malaysia & Indonesia
WellianWiranto@ocbc.com
Terence Wu
FX Strategist
TerenceWu@ocbc.com
Howie Lee
Thailand, Korea & Commodities
HowieLee@ocbc.com
Carie Li
Hong Kong & Macau
carierli@ocbcwh.com
Dick Yu
Hong Kong & Macau
dicksnyu@ocbcwh.com

Credit Research

Andrew Wong
Credit Research Analyst
WongVKAM@ocbc.com
Ezien Hoo
Credit Research Analyst
EzienHoo@ocbc.com
Wong Hong Wei
Credit Research Analyst
WongHongWei@ocbc.com
Seow Zhi Qi
Credit Research Analyst
ZhiQiSeow@ocbc.com

This publication is solely for information purposes only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This publication should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this publication may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This publication may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, they should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. OCBC Bank, its related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial services to such issuers. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products.

This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).